Project description
Identification of microbiome-based biomarkers for end-stage liver disease
The end stage of liver disease is decompensated cirrhosis and progression towards acute-on-chronic liver failure (ACLF), which presents with systemic inflammation and organ failure and has a dismal prognosis. Emerging evidence indicates that the gut microbiome is implicated in liver cirrhosis, but the underlying mechanism remains to be elucidated. MICROB-PREDICT is a programme of excellence funded by the EU that aims to investigate the role of the microbiome in the gut–liver interaction. Researchers will also identify microbiome-based biomarkers associated with end-stage liver disease and generate data from large patient cohorts. Collectively, this information will enable accurate patient stratification and pave the way for personalised therapies.
Objective
Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment.
The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders.
MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
08021 Barcelona
Spain
See on map
Participants (23)
4032 Debrecen
See on map
7100 Vejle
See on map
1165 Kobenhavn
See on map
69117 Heidelberg
See on map
75015 PARIS 15
See on map
80539 Munchen
See on map
31670 Labege
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75007 Paris
See on map
Participation ended
60323 Frankfurt Am Main
See on map
3000 Leuven
See on map
2333 ZA Leiden
See on map
08007 Barcelona
See on map
69126 Heidelberg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08193 Cerdanyola Del Valles
See on map
WC1E 6BT London
See on map
0313 Oslo
See on map
1050 Bruxelles / Brussel
See on map
82256 FURSTENFELDBRUCK
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
WC2R 2LS London
See on map
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
1203 Geneve
See on map
48149 MUENSTER
See on map